

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

Benedikt Fischer, PhD, Cayley Russell, MA, Pamela Sabioni, PhD, Wim van den Brink, MD, PhD, Bernard Le Foll, MD, PhD, Wayne Hall, PhD, Jürgen Rehm, PhD, and Robin Room, PhD

Background. Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors that are modifiable by the user, evidence-based Lower-Risk Cannabis Use Guidelines (LRCUG)—akin to similar guidelines in other health fields—offer a valuable, targeted prevention tool to improve public health outcomes.

Objectives. To systematically review, update, and quality-grade evidence on behavioral factors determining adverse health outcomes from cannabis that may be modifiable by the user, and translate this evidence into revised LRCUG as a public health intervention tool based on an expert consensus process.

Search methods. We used pertinent medical search terms and structured search strategies, to search MEDLINE, EMBASE, PsycINFO, Cochrane Library databases, and reference lists primarily for systematic reviews and meta-analyses, and additional evidence on modifiable risk factors for adverse health outcomes from cannabis use.

Selection criteria. We included studies if they focused on potentially modifiable behavior-based factors for risks or harms for health from cannabis use, and excluded studies if cannabis use was assessed for therapeutic purposes.

Data collection and analysis. We screened the titles and abstracts of all studies identified by the search strategy and assessed the full texts of all potentially eligible studies for inclusion; 2 of the authors independently extracted the data of all studies included in this review. We created Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow-charts for each of the topical searches. Subsequently, we summarized the evidence by behavioral factor topic, quality-graded it by following standard (Grading of Recommendations Assessment, Development, and Evaluation; GRADE) criteria, and translated it into the LRCUG recommendations by the author expert collective on the basis of an iterative consensus process.

Main results. For most recommendations, there was at least “substantial” (i.e., good-quality) evidence. We developed 10 major recommendations for lower-risk use: (1) the most effective way to avoid cannabis use–related health risks is abstinence, (2) avoid early age initiation of cannabis use (i.e., definitively before the age of 16 years), (3) choose low-potency tetrahydrocannabinol (THC) or balanced THC-to-cannabidiol (CBD)-ratio cannabis products, (4) abstain from using synthetic cannabinoids, (5) avoid combusted cannabis inhalation and give preference to nonsmoking use methods, (6) avoid deep or other risky inhalation practices, (7) avoid high-frequency (e.g., daily or near-daily) cannabis use, (8) abstain from cannabis-impaired driving, (9) populations at higher risk for cannabis use–related health problems should avoid use altogether, and (10) avoid combining previously mentioned risk behaviors (e.g., early initiation and high-frequency use).

Authors’ conclusions. Evidence indicates that a substantial extent of the risk of adverse health outcomes from cannabis use may be reduced by informed behavioral choices among users. The evidence-based LRCUG serve as a population-level education and intervention tool to inform such user choices toward improved public health outcomes. However, the LRCUG ought to be systematically communicated and supported by key regulation measures (e.g., cannabis product labeling, content regulation) to be effective. All of these measures are concretely possible under emerging legalization regimes, and should be actively implemented by regulatory authorities. The population-level impact of the LRCUG toward reducing cannabis use–related health risks should be evaluated.

Public health implications. Cannabis control regimes are evolving, including legalization in North America, with uncertain impacts on public health. Evidence-based LRCUG offer a potentially valuable population-level tool to reduce the risk of adverse health outcomes from cannabis use among (especially young) users in legalization contexts, and hence to contribute to improved public health outcomes. (*Am J Public Health.* 2017;107:e1–e12. doi:10.2105/AJPH.2017.303818)

PLAIN-LANGUAGE SUMMARY

Cannabis (e.g., marijuana) products are used by many (especially young) people, yet use comes with various health risks. As cannabis use and distribution are becoming legal in different countries (e.g., Canada), efforts are needed to reduce health risks from use. Therefore, a group of international experts developed the Lower-Risk Cannabis Use Guidelines (LRCUG). The LRCUG are based on scientific evidence, identifying

behaviors within the user’s control that influence the risk of health consequences from cannabis use. Our expert group systematically reviewed up-to-date evidence, and translated it into concrete recommendations on how to practically reduce such health risks. A total of 10 concrete recommendations are provided (similar to guidelines in other areas of health) extending, for example, to age of cannabis use initiation, use frequency or patterns, cannabis products (i.e., low- vs

high-tetrahydrocannabinol content) used, and cannabis use and driving. Especially in settings where cannabis use is legal and regulated, the LRCUG can be distributed by health authorities as a science-based information tool for cannabis users to modify their use toward reducing at least some of the health risks. Hence, the LRCUG may function as a valuable measure to reduce negative health outcomes from cannabis use in environments where such use is legal.

Cannabis is the most commonly used illicit drug globally, and Canada has among the highest use rates.^{1,2} Some 10% to 15% of general-population adults and 25% to 30% of adolescents or young adults report current (i.e., past-year) cannabis use.³ Although the public health burden of cannabis use is clearly smaller than for alcohol, tobacco, and other illicit drugs, it is associated with risks for various adverse health outcomes, although causality is not established for all of these (for key reviews see Degenhardt et al.,² Volkow et al.,⁴ Hall and Degenhardt,⁵ World Health Organization,⁶ and National Academies of Science, Engineering, and Medicine⁷). Strongest evidence exists for the following associations: acute cognitive and psychomotor impairments, motor-vehicle accidents (MVAs), brain development and chronic functioning, dependence and psychosis, pulmonary or bronchial system problems, and poorer pregnancy outcomes.^{4–12} A substantial proportion of these problems occurs in users who initiated use in adolescence or continued to use frequently into adulthood.^{4,13–17} Internationally, dependence has been assessed as the only contributor to cannabis-attributable disease burden^{2,18}; in Canada, the main contributors have been identified as being MVAs and disorders (e.g., dependence).^{19,20}

Prohibition of recreational cannabis use has long been the dominant policy model,^{21,22} yet it has been increasingly recognized as ineffective. As a consequence, a growing number of jurisdictions has implemented cannabis policy reforms, including full legalization approaches for use and supply. Legalization has been implemented in several US states and in Uruguay,^{23–26} and awaits nationwide implementation in Canada—the first G7 country—to be enacted shortly.^{27,28} The Canadian legalization framework emphasizes objectives of public health, although experiences from US legalization states suggest that public health outcomes there have not necessarily been improved throughout.²⁵

Extensive data suggest that many cannabis use-associated harms—or at least their severity—are influenced by modifiable behavioral factors or user choices. Moreover, in legalization environments, there is opportunity for interventions to modify

cannabis users' behavior toward improved public health outcomes. Expert assessments of evidence have generated similar population-oriented interventions for alcohol^{29,30} and other health areas (e.g., nutrition, sexual health, and physical activity).^{31–35} Thus, Lower-Risk Cannabis Use Guidelines (LRCUG) may be a worthwhile public health intervention for cannabis, particularly following legalization of use. Although an initial version of LRCUG was developed for Canada several years ago,³⁶ scientific evidence on cannabis use and outcomes has substantially evolved since then; this article presents a comprehensive evidence update and corresponding revisions of the original LRCUG's recommendations. The LRCUG are primarily aimed at individuals, initially in the context of Canada, who have made the choice to use cannabis, as a knowledge-based tool to lower their risk of harms. As such, the LRCUG constitute an evidence-based resource for governments and other relevant organizations for implementation; they may be adapted for application in sociocultural contexts other than North America.

METHODS

Two main methodological components underlie the revised LRCUG: (1) a set of systematic reviews of modifiable risk factors for cannabis use-related health harms and (2) grading of this evidence and the revision of the LRCUG's recommendations by expert author consensus. We conducted the systematic reviews in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines.³⁷

ABOUT THE AUTHORS

Benedikt Fischer, Cayley Russell, Pamela Sabioni, and Jürgen Rehm are with the Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario. Wim van den Brink is with the Amsterdam Institute for Addiction Research, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Bernard Le Foll is with the Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto. Wayne Hall is with the Centre for Youth Substance Abuse Research, Faculty of Health and Behavioural Sciences, University of Queensland, Brisbane, Australia. Robin Room is with the Centre for Alcohol Policy Research, La Trobe University, Melbourne, Australia.

Correspondence should be sent to Benedikt Fischer, PhD, Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell St, Toronto, Ontario, M5S 2S1, Canada (e-mail: benedikt.fischer@utoronto.ca). Reprints can be ordered at <http://www.ajph.org> by clicking the "Reprints" link.

This article was accepted March 25, 2017.

doi: 10.2105/AJPH.2017.303818

To identify relevant systematic reviews and meta-analyses on the different risk factor topics, we searched studies published in any language (January 1, 2010, to December 30, 2016) in the following databases: MEDLINE, EMBASE, PsycINFO, and Cochrane Library for Systematic Reviews. We developed separate search strategies for each review topic; these were based on the strategy developed for MEDLINE but revised appropriately for each database (see Appendix A, available as a supplement to the online version of this article at <http://www.ajph.org>, for details). In addition, we consulted the recent seminal reviews on cannabis and health from the World Health Organization⁶ and the US National Academies of Sciences, Engineering, and Medicine⁷ as relevant systematic review sources. We checked the reference lists of all relevant studies, and hand-searched relevant articles to identify additional relevant studies not retrieved by the electronic searches.

Inclusion and Exclusion Criteria

We included studies if they focused on potentially modifiable behavior-based factors for risks or harms of cannabis use, and we excluded them if cannabis was assessed for therapeutic purposes. We developed specific inclusion and exclusion criteria for each topic of this review (see Appendix B, available as a supplement to the online version of this article at <http://www.ajph.org>, for details).

Two of the authors (C. R. and P. S.) independently screened the titles and abstracts of all publications identified by the search strategy. We retrieved all potentially eligible studies as full-text articles and independently assessed them for inclusion and exclusion. In instances of doubt or

discordance, the review authors discussed the data and reached consensus for all such cases without the need for arbitration. P. S. and C. R. independently extracted data from all studies included in this systematic review (see Figure A, available as a supplement to the online version of this article at <http://www.ajph.org>, for PRISMA flow charts for each of the subtopic searches).

Evidence Grading and Recommendations Development

We quality-graded the resulting evidence according to a widely used grading scheme^{38,39} in a 2-step process. Four of the authors (B. F., J. R., C. R., and P. S.) first did this individually and then full author group consensus was developed. Evidence grades assigned are included with the recommendations (see the box on the next page); an extended version of the recommendations with detailed explanation of the evidence grades is available as a supplement to the online version of this article (available at <http://www.ajph.org>). The selected studies were rated according to the following evidence grades (i.e., same criteria as used by the National Academies of Sciences, Engineering, and Medicine⁷):

1. **Conclusive:** based on good-quality studies and no credible opposing findings;
2. **Substantial:** based on several supportive findings from good-quality studies with few opposing studies;
3. **Moderate:** based on several supportive findings from good- to fair-quality studies with few or no credible opposing findings; a general conclusion can be made, but limitations, including chance, bias, and confounding factors, cannot be ruled out;
4. **Limited:** supportive findings from fair-quality studies or mixed findings with most favoring one conclusion, or no firm conclusions; and
5. **None or Insufficient:** based on mixed findings, a single poor study, or the endpoint has not been studied, with substantial uncertainty attributable to chance, bias, and confounding factors.

Importantly, most studies reviewed were cross-sectional and naturalistic, implying caution with causal interpretations and conclusions about the magnitudes of effects.

We then translated the reviewed evidence into revised recommendations using established process standards.^{39–42} This again involved a 2-step process: 2 of the authors (B. F., J. R.) generated draft recommendations (either by revising original or drafting new recommendations) and the authors subsequently discussed and collectively revised the recommendations until they reached consensus. Both the topical evidence reviews and corresponding recommendations are presented in sequential order related to the cannabis use continuum.

RESULTS

The results are presented by subtopics of evidence informing the LRCUG recommendations.

Early Use Initiation

There is substantial evidence that early onset (e.g., before age 18 years) cannabis use is associated with a higher risk of dependence and later problem outcomes. This may be because cannabis use in adolescence impairs various aspects of brain development, especially if intensive and ongoing during the brain development period (until the mid-20s).^{43–46} For example, early-onset cannabis users have shown alterations of white and gray brain matter and cortical thickness^{47–49}; lowered functional connectivity, IQ, and cognitive functioning⁵⁰; and greater behavioral impulsivity.⁵¹ These may reflect factors explaining both early onset of cannabis use and later outcomes.

Associations between early-onset cannabis use and mental health problems and dependence outcomes are well-established.^{52–54} Compared with later onset, early-onset users commonly used cannabis more intensively and subsequently showed poorer cognitive and executive functioning.⁵⁵ The risk of cannabis dependence was almost double in early- versus late-onset users (1 in 6 vs 1 in 10, respectively).⁵⁶ Among cannabis-dependent users, early onset is associated with subsequent poorer attention, verbal learning and memory, impulse control, and executive functioning outcomes.^{57,58}

Individual studies have documented further associations for early-onset use, for

example with elevated risk of developing mental health problems, including depressive symptoms,^{59,60} and psychotic symptoms.^{61,62} Conversely, no associations were found between cannabis use and psychosis,⁶¹ or reduced IQ,⁶³ among those initiating use after age 18 years. In a longitudinal sibling-pair study, those initiating use before age 16 years had increased risk of nonaffective psychosis (odds ratio [OR] = 2.2; 95% confidence interval [CI] = 1.1, 4.5), delusions (OR = 4.2; 95% CI = 4.2, 5.8), and experiencing hallucinations (OR = 2.8; 95% CI = 1.9, 4.1); the association persisted when examined in sibling pairs.⁶⁴ Early-use initiators (by age 14 years) were 4 times more likely to develop cannabis dependence and 3 times more likely to have an MVA than those starting use after age 21 years.⁶⁵ In a subsample of male twins discordant for cannabis use, early-onset users had elevated risk of subsequent other substance use, and for alcohol and illegal drug dependence, compared with controls.^{66,67} In a meta-analysis of longitudinal studies, never-users of cannabis by age 18 years had greater odds of high-school and university degree attainment, compared with those who started use before age 15 years.⁶⁸ Other studies demonstrated poorer educational outcomes, including a risk of early school leaving or postsecondary degree noncompletion.^{17,69}

Choice of Cannabis Products

In recent years, the psychoactive properties of cannabis products have substantially changed with evolving production techniques. Although cannabis contains many cannabinoids, a consistent increase in levels of tetrahydrocannabinol (THC)—the main psychoactive agent—in cannabis has been observed over the past decades,⁷⁰ rising to as much as 20% to 25% or more in some places.^{6,71–73} Meanwhile, cannabis concentrates or synthetic cannabinoid products can contain up to 80% to 90% THC or more potent cannabinoid agonists.^{6,71,74}

High THC content in cannabis has been identified as a risk factor for acute and chronic adverse outcomes, including mental health problems and dependence.^{4,5,75} For example, frequent use of high-potency cannabis (“skunk”) has been associated with marked effects on memory, increased

RECOMMENDATIONS

Recommendation 1: The most effective way to avoid any risks of cannabis use is to abstain from use. Those who decide to use need to recognize that they incur risks of a variety of—acute and long-term—adverse health and social outcomes. These risks will vary in their likelihood and severity with user characteristics, use patterns, and product qualities, and so may not be the same from user to user or use episode to another. *[Evidence Grade: None required.]*

Recommendation 2: Early initiation of cannabis use (i.e., most clearly that which begins before age 16 years) is associated with multiple subsequent adverse health and social effects in young adult life. These effects are particularly pronounced in early-onset users who also engage in intensive and frequent use. This may be in part because frequent cannabis use affects the developing brain. Prevention messages should emphasize that, the later cannabis use is initiated, the lower the risks will be for adverse effects on the user's general health and welfare throughout later life. *[Evidence Grade: Substantial.]*

Recommendation 3: High THC-content products are generally associated with higher risks of various (acute and chronic) mental and behavioral problem outcomes. Users should know the nature and composition of the cannabis products that they use, and ideally use cannabis products with low THC content. Given the evidence of CBD's attenuating effects on some THC-related outcomes, it is advisable to use cannabis containing high CBD:THC ratios. *[Evidence Grade: Substantial.]*

Recommendation 4: Recent reviews on synthetic cannabinoids indicate markedly more acute and severe adverse health effects from the use of these products (including instances of death). The use of these products should be avoided. *[Evidence Grade: Limited.]*

Recommendation 5: Regular inhalation of combusted cannabis adversely affects respiratory health outcomes. While alternative delivery methods come with their own risks, it is generally preferable to avoid routes of administration that involve smoking combusted cannabis material (e.g., by using vaporizers or edibles). Use of edibles eliminates respiratory risks, but the delayed onset of psychoactive effect may result in the use of larger than intended doses and subsequently increased (mainly acute, e.g., from impairment) adverse effects. *[Evidence Grade: Substantial.]*

Recommendation 6: Users should avoid practices such as “deep inhalation,” breath-holding, or the Valsalva maneuver to increase psychoactive ingredient absorption when smoking cannabis, as these practices disproportionately increase the intake of toxic material into the pulmonary system. *[Evidence Grade: Limited.]*

Recommendation 7: Frequent or intensive (e.g., daily or near-daily) cannabis use is strongly associated with higher risks of experiencing adverse health and social outcomes related to cannabis use. Users should be aware and vigilant to keep their own cannabis use—and that of friends, peers, or fellow users—occasional (e.g., use only on 1 day/week, weekend use only, etc.) at most. *[Evidence Grade: Substantial.]*

Recommendation 8: Driving while impaired from cannabis is associated with an increased risk of involvement in motor-vehicle accidents. It is recommended that users categorically refrain from driving (or operating other machinery or mobility devices) for at least 6 hours after using cannabis. This wait time may need to be longer, depending on the user and the properties of the specific cannabis product used. Besides these behavioral recommendations, users are bound by locally applicable legal limits concerning cannabis impairment and driving. The use of both cannabis and alcohol results in multiply increased impairment and risks for driving, and categorically should be avoided. *[Evidence Grade: Substantial.]*

Recommendation 9: There are some populations at probable higher risk for cannabis-related adverse effects who should refrain from using cannabis. These include individuals with predisposition for, or a first-degree family history of, psychosis and substance use disorders, as well as pregnant women (primarily to avoid adverse effects on the fetus or newborn). These recommendations, in part, are based on precautionary principles. *[Evidence Grade: Substantial.]*

Recommendation 10: While data are sparse, it is likely that the combination of some of the risk behaviors listed above will magnify the risk of adverse outcomes from cannabis use. For example, early-onset use involving frequent use of high-potency cannabis is likely to disproportionately increase the risks of experiencing acute or chronic problems. Preventing these combined high-risk patterns of use should be avoided by the user and a policy focus. *[Evidence Grade: Limited.]*

Note. A detailed rationale for each evidence grade is provided as a supplement to the online version of this article at <http://www.ajph.org>.

paranoia, and greater dependence severity in (especially younger) users in the United Kingdom.⁷⁶ In a case-control study, use of high-THC cannabis was associated with a 3-times-elevated risk of psychotic disorder and, hence, with 1 in 4 of incident cases.⁷⁷ Use of high-potency “wax dabs” has been linked to cannabis-induced psychosis among individuals with no psychiatric history.⁷⁸

There is some evidence that users of cannabis products with higher THC potency titrate their doses (i.e., use less of higher-potency products to achieve desired psychoactive effects).^{5,79} Among experienced users, a positive association between THC concentration and cannabis dose per joint has been observed, but the THC concentration was negatively associated with inhalation volume, leading to only a partial titration of dose (i.e., high-THC product users still obtained more THC than low-THC product users).⁸⁰ Similarly, in another naturalistic study, the amount of cannabis per joint was negatively associated with THC concentrations, estimating a 0.1-gram reduction in the amount of cannabis used if it contained 14% versus 4% THC content.⁸¹

Other cannabinoids besides THC may influence the adverse effects of cannabis. Specifically, cannabidiol (CBD) is increasingly understood as a cannabinoid that may attenuate some of THC’s adverse effects.^{82–86} Several randomized controlled trials and systematic reviews suggest that CBD can block the psychotogenic effects of THC,^{83,87–90} and mitigate THC’s intoxicating, sedating, and cardiovascular effects.⁸⁶ However, a systematic review concluded that high doses of CBD are needed to inhibit the effects of even low doses of THC.⁹¹

A recent development has been the availability of potent synthetic cannabinoid products (e.g., Spice, K2). These have a distinct pharmacology and toxicology and have been associated with an array of severe adverse side effects, including acute cognitive impairment, psychosis and anxiety, strokes and seizures, myocardial infarction, tachycardia, nausea, and fatalities.^{92–94} These effects are commonly more severe than those from organic cannabis use.^{95,96} Another systematic review similarly found

adverse acute and chronic mental effects (e.g., anxiety, psychosis, dependence) to be common among regular users of synthetic cannabinoid products.⁹⁷ Emergency department contacts related to synthetic cannabinoids have increased among younger users in recent years.^{98–100}

Cannabis Use Practices

Although alternative use practices exist, smoking burnt (combusted) cannabis remains the most common route of administration in North America,^{101,102} commonly in combination with tobacco.^{6,103} These use practices are associated with a variety of risks.

Systematic reviews and major studies have identified various pulmonary or bronchial problems (e.g., coughing, excessive sputum, wheezing, shortness of breath) as well as acute bronchitis and impaired respiratory functioning associated cannabis smoking.^{11,104–108} Although many of these symptoms appear to be associated with use intensity, they may be reversible following cessation.^{109,110} Findings are more equivocal for other respiratory diseases. For example, emphysematous lung bullae have been detected among young cannabis smokers.¹¹¹ There is mixed evidence for associations of cannabis smoking with lung cancer, with only some studies reporting associations; among those showing associations, the risk is moderately elevated (1.5- to 4-fold)^{108,112–114} and associations continue to be inconclusive mainly because of confounding by tobacco use.^{113,114}

Some specific cannabis smoking practices can acutely increase respiratory health risks. For example, breath-holding or deep inhalation practices—intended to intensify the absorption of psychoactive components—increase the intake of hazardous byproducts (e.g., carcinogens, tar and other toxins, carbon monoxide).^{113,115–118} These effects are further amplified by concurrent smoking of cannabis and tobacco.

Various alternative administration routes for cannabis use have emerged, which, however, come with their own risks. For example, bong or water pipes may reduce burnt particle inhalation while increasing tar or particulate matter intake; infectious disease (e.g., pulmonary tuberculosis)

transmission has also been reported among users.^{119–121} As for newer options, vaporizer devices eliminate cannabis combustion and thus reduce toxic compound intake and related pulmonary problems.^{122,123} In 2 experimental studies, respiratory problems (including bronchitis) significantly improved among users switching to vaporizer use, but the lag in onset of psychoactive effects led to higher dosing.^{124,125} However, no rigorous studies exist on the long-term effects of vaporizer use.¹²⁶ For cannabis e-cigarette devices, formaldehyde particles have been detected at higher voltage that may expose users to risky toxins.¹²⁷ “Dabbing” (the inhaling of flash-vaporized cannabis concentrates) has been associated with elevated risks of hydrocarbon burns and inhalation of solder, rust, and benzene, in addition to greater impairment, tolerance, and withdrawal symptoms.^{71,128,129}

Ingested (e.g., edible or liquid or oils) cannabis products eliminate the risks of inhalation of combusted cannabis smoke or vapor.¹¹⁵ Concerns exist that “edibles” may lower the perceived risks of using cannabis (e.g., leading to earlier initiation or increased use). Other acute risks include the delayed absorption of THC and consequently delayed onset of psychoactive effects that reduces edibles users’ ability to titrate their doses.¹²⁸ This may result in larger-than-intended amounts of THC consumed, possibly contributing to increases in edibles-related poisonings and hospitalizations where these products are available (e.g., Colorado^{130,131}). Furthermore, edible cannabis products can also be accidentally ingested by children who then require treatment.¹³²

Frequency or Intensity of Use

Frequency or intensity of use is a strong predictor of both acute and chronic cannabis-related problems. Use intensity or frequency is a common epidemiological proxy measure, which is typically defined as (near-) daily use and compared with less-frequent use. Ideally, these indicators should be complemented by other measures, such as dose or potency, but this is rarely the case.¹³³ Frequent cannabis use has increased substantially among (especially younger) users in the United States.¹³⁴

Systematic reviews have found associations between the frequency or intensity of cannabis use and various adverse health outcomes, including mental health problems,^{5,10,135,136} cardiovascular problems,¹³⁷ MVAs,¹³⁸ suicidality,¹³⁹ changes in brain structure, and neurocognitive effects.^{140,141} Specifically, neuroimaging studies have found morphological brain alterations and neurocognitive effects in both adolescents and adults related to intensity of cannabis use.^{140–142} In case-control studies, use intensity has had an inverse association with brain volume and structure integrity.^{143–146} Thus, the magnitude of brain abnormalities and the persistence of acute impairment of executive functions (e.g., cognition, memory, psychomotor control) may be influenced by use intensity.^{9,147,148} At the same time, there is evidence for tolerance effects resulting in reduced cognitive impairment among frequent or chronic users.^{148,149}

Key individual studies complement the previously mentioned review findings on mental health and other outcomes. For instance, studies from various countries have identified cannabis use frequency as a predictor of psychosis,^{150–152} depressive symptoms, mania, and suicide.^{153–155} In a longitudinal cohort, daily cannabis use was associated with anxiety disorder (OR = 2.5; 95% CI = 1.2, 5.2) and cannabis dependence (OR = 2.2; 95% CI = 1.1, 4.4); those with persistent daily cannabis use at age 29 years remained at elevated odds for anxiety disorder (OR = 3.2; 95% CI = 1.1, 9.2).¹⁵⁶ The risk of cannabis dependence was 5-fold among daily versus infrequent users in Australia.¹⁵⁷ Frequent use predicted dependence severity among adult users in the United Kingdom.⁷⁶ An exception may be a Dutch study in which use frequency was not associated with incidence of dependence; however, this study involved frequent and age-limited users only.¹⁵⁸ In combined analyses of longitudinal cohorts, daily cannabis users by age 17 years had significant reductions in high-school completion and degree attainment (OR = 0.4; 95% CI = 0.2, 0.7), and increased odds of later cannabis dependence (OR = 18.0; 95% CI = 9.4, 34.1), other illicit drug use (OR = 7.8; 95% CI = 4.5, 13.6), and suicide attempts (OR = 6.8;

95% CI = 2.0, 22.9).¹⁵⁹ Similar associations with educational, socioeconomic, and other substance use outcomes have been shown.^{5,17,160–162} Several studies have found that MVA risk is increased among frequent users.^{163,164} Use frequency also predicted higher overall and specific problem domain outcomes on the Alcohol, Smoking, and Substance Involvement Screening Test; daily or near-daily users were at least 9 times more likely to experience problems than infrequent users.¹⁶⁵

Cannabis Use and Driving

Cannabis use acutely impairs key executive functions critical for driving, including cognition, attention, memory, decision-making, and psychomotor functioning. This occurs in a dose-dependent way, although the magnitude and persistence of impairments may vary with use patterns, THC concentration, tolerance, metabolism, and other factors.^{9,147,148,166} Some of these impairments have been found to persist after acute intoxication, particularly in chronic users.⁹

Following cannabis intake, peak THC plasma concentrations (around 100 ng/mL) are usually reached within approximately 5 to 30 minutes and generally taper off approximately 2 to 4 hours later.^{149,167–170} However, intoxication and cognitive impairments may persist beyond THC plasma concentration peaks, yet typically clear within approximately 3 to 6 hours.^{149,170–173} Higher THC or other cannabinoid concentration or ingested cannabis products (with an extended absorption period) can have more pronounced and persistent effects.^{171,174} Although these effects are based on the typical pharmacokinetics of THC, they may vary with inhalation intensity, lung capacity, and other factors.⁶

Epidemiological studies have clearly established that acute cannabis impairment increases the risk of MVA involvement, including fatal collisions (a notable exception: National Highway Traffic Safety Administration¹⁷⁵). Several meta-analyses and reviews concluded that there is an approximate 1.3- to 3-fold (low-to-medium magnitude) increase in MVA risk after cannabis use.^{8,163,164,176} A recent Canadian case-crossover study found cannabis use to

be associated with a 4-fold increase in MVA involvement.¹⁷⁷ Risk of MVA involvement increases in a dose-related way with THC concentration or frequency of cannabis use.^{163,164} This risk is substantially higher when cannabis and alcohol use are combined.^{178–182}

As cannabis-impaired driving has become more common, especially among young drivers,^{183–187} attempts have been made to define threshold levels of blood-THC concentration equivalent to blood-alcohol content limits. This has been methodologically challenging, and no gold-standard threshold exists. Some studies concluded that blood-THC concentrations ranging from about 2 to 8 nanograms per milliliter (ng/mL; whole blood) resulted in the equivalent driving impairment to 0.05 blood-alcohol content,^{164,179,188} whereas the final recommendations of the Driving Under the Influence of Drugs, Alcohol, and Medicines study were 1 ng/mL in whole blood or saliva.¹⁸⁹ Some US states with *per se* laws have blood-THC concentration limits of 5 ng/mL (whole blood), whereas some European countries (e.g., Norway, the Netherlands) have thresholds of less than 5 ng/mL,^{189–191} and others (e.g., Australia) have defined any detectable recent use as impairment.¹⁹² These legal limits, which cannot be reliably self-assessed by users, may thus translate into stricter restrictions on driving than the behavioral parameters outlined previously.

Special Risk Populations

Some users with pre-existing conditions should probably abstain from using cannabis. For example, several studies have concluded that a substantial proportion of cannabis-attributable psychosis occurs among users with a family or personal history of psychosis, and a genetic predisposition to psychosis may be triggered or amplified by cannabis use.^{5,193–197} Assuming that risk of psychosis from family history and cannabis use are multiplicative, someone with a first-degree relative with a history of psychosis has a 10% baseline risk, which is doubled if they become regular users.^{62,198} It is unclear whether such dynamics also exist for other mental health risks, such as depression, anxiety, or suicide,

for which associations with cannabis have been shown.^{154,155,199–202} However, previous experiences with or family histories of substance use disorders should encourage prudence for cannabis use.

A systematic review found that women who used cannabis during pregnancy had increased odds of anemia (pooled OR = 1.4; 95% CI = 1.1, 1.7), decreased birth weight (pooled OR = 1.8; 95% CI = 1.0, 3.0), and placement in neonatal care units (pooled OR = 2.0; 95% CI = 1.3, 3.2).¹² Maternal cannabis use has been associated with fetal growth reduction and decreased birth weight in newborns,²⁰³ as well as with child development and behavior problems, poor school performance, and illicit drug use in children.^{204–207} Case-control studies have found associations for different cancers among children when maternal cannabis use occurred during pregnancy, but provide weak evidence for causal associations.^{137,208–210}

DISCUSSION

Cannabis control policy in Canada, reflecting developments elsewhere, is shifting to legalization of recreational use and supply, with the declared objective of improving public health outcomes.^{27,28} Experiences from other jurisdictions have suggested that legalization does not necessarily—at least in the short run—translate into consistent public health improvements but may increase specific problems.^{24,25,211,212} Nonetheless, one of the distinct advantages of legalization is that it allows open and direct information of users on risk behaviors, product properties, and more with the aim of reducing harmful outcomes from use.^{22,213,214} Evidence-based guidelines for cannabis users on how to reduce risks for acute and chronic harms from use, if widely adopted, may reduce the harm burden for both individuals and the population, and thus constitute a valuable public health tool. On this basis, we have undertaken a comprehensive update and revision, based on a systematic review of new evidence, of previously developed LRCUG for Canada.³⁶ These were developed when cannabis was still criminally prohibited; however, impending legalization has entailed strong reasons and demand for updated LRCUG.

As the data show, cannabis use is associated with a variety of health risks, including several for which the evidence is “substantial.” The primary challenge for public health-oriented cannabis policy is to prevent adolescent or young adult cannabis users from developing severe—acute or chronic—health problems from use.^{4,16,215} Our review has identified multiple concrete risk factors for cannabis-related health problems, which are modifiable by the user, offering the potential for reduced risks based on recommendations as presented by the LRCUG. Most of the evidence of risk factors and outcomes underlying the recommendations is “substantial” as per established evidence-grading standards.^{7,39}

For example, frequent or intense cannabis use is a well-documented determinant of several key adverse health outcomes and a behavior that can be modified by users. Similarly, the evidence for risks associated with early initiation of cannabis use is strong. Successfully addressing this risk factor hinges on effective prevention efforts (e.g., by parents, teachers, and peers) to delay first use. For cannabis-impaired driving, the strong evidence for risk of MVAs warrants the categorical recommendation that users abstain from driving for at least the acute period of impairment identified by current scientific evidence. For other risk factors—for example, the use of alternative delivery methods for cannabis use to avoid smoking-related health harms—the evidence is weaker because of an absence of rigorous studies. Here, better studies and data are urgently needed. Similarly, the evidence base for special risk populations to warrant abstention from cannabis use is relatively thin, and thus limited to the 2 subgroups indicated. There may be empirical grounds to extend future recommendations to other subgroups (e.g., with cardiovascular or other predispositions to specific health problems).

On the basis of our rigorous review methodology and expert consensus-based evidence grading and recommendations development, we are confident in the overall quality and relevance of the recommendations presented. At the same time, specific cannabis use-related risk factors and outcomes are influenced by other (intrinsic and extrinsic) factors (e.g., genetic profiles, cobehaviors, socio-environmental factors); thus, the applicability of

the recommendations certainly varies among individual users.^{6,216–220} Also unclear is the extent of concrete health harm that may be avoided from each of the recommendations; this should be systematically assessed.

Importantly, behavior-oriented public health interventions like the LRCUG require effective implementation and uptake to have impact.^{221,222} In addition, they need to be supported by information for users—for example, about the specific content details of cannabis products, facilitated by measures such as product testing and labeling.²¹⁴ The implementation of interventions like the LRCUG does not fall into the realm of science but requires systematic efforts by governmental and non-governmental institutions and other key stakeholders. The evidence for impact of similar endeavors (e.g., alcohol-, food and nutrition-, and safer sex-related guidelines) in other areas is mixed.^{33–35,223,224}

Given impending legalization, an acute need for public health tools to further population-oriented prevention goals exists in Canada, which the revised LRCUG aim to serve. The LRCUG can be adapted for use in other sociocultural environments beyond North America. Ideally, their impact should be evaluated toward an evidence base concerning effective public health interventions within the emerging cannabis policy paradigm of legalization. **AJPH**

CONTRIBUTORS

B. Fischer led the overall study and article writing. B. Fischer, P. Sabioni, and J. Rehm designed the data search and analysis strategy. J. Rehm led the evidence quality grading. C. Russell and P. Sabioni executed the data searches, extraction, and summaries. All authors (including W. van den Brink, B. Le Foll, W. Hall, and R. Room) equally and substantially contributed to data analysis and interpretation, evidence quality grading, and article and recommendations drafting and revising, as well as approved the final version of the article.

ACKNOWLEDGMENTS

B. Fischer acknowledges funding from Canadian Institutes of Health Research for the Ontario Canadian Research Initiative in Substance Misuse Node Team grant (SMN-139150) in supporting the present work.

The authors dedicate this work to the late Elliot Goldner, MD, MHSc, a distinguished academic and special colleague who had substantially contributed to the original Lower-Risk Cannabis Use Guidelines, and who suddenly passed away in late 2016.

HUMAN PARTICIPANT PROTECTION

Institutional review board approval was not needed for this study as it did not involve human participants.

REFERENCES

1. *World Drug Report 2015*. Vienna, Austria: United Nations Office on Drugs and Crime; 2015.
2. Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study [correction in *PLoS One*. 2016;11(10):e0165221]. *PLoS One*. 2013;8(10):e76635.
3. *Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012*. Ottawa, ON: Health Canada; 2014.
4. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. *N Engl J Med*. 2014;370(23):2219–2227.
5. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009;374(9698):1383–1391.
6. The health and social effects of nonmedical cannabis use. Geneva, Switzerland: World Health Organization; 2016.
7. National Academies of Sciences, Engineering, and Medicine. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press; 2017.
8. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. *Addiction*. 2016;111(8):1348–1359.
9. Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition—a systematic review. *Biol Psychiatry*. 2016;79(7):557–567.
10. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull*. 2016;42(5):1262–1269.
11. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications. *Arch Intern Med*. 2007;167(3):221–228.
12. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open*. 2016;6(4):e009986.
13. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in adolescence. *Mol Cell Endocrinol*. 2008;286(1–2 suppl 1):S108–S113.
14. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. *Curr Drug Abuse Rev*. 2008;1(2):114–123.
15. Bava S, Tapert SF. Adolescent brain development and the risk for alcohol and other drug problems. *Neuropsychol Rev*. 2010;20(4):398–413.
16. Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. *Lancet*. 2004;363(9421):1579–1588.
17. Fergusson DM, Boden JM. Cannabis use and later life outcomes. *Addiction*. 2008;103(6):969–976.
18. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. *Lancet*. 2013;382(9904):1564–1574.
19. Intiaz S, Shield KD, Roerecke M, et al. The burden of disease attributable to cannabis use in Canada in 2012. *Addiction*. 2016;111(4):653–662.
20. Fischer B, Intiaz S, Rudzinski K, Rehm J. Crude estimates of cannabis-attributable mortality and morbidity in Canada—implications for public health focused intervention priorities. *J Public Health (Oxf)*. 2016;38(1):183–188.
21. Fischer B, Ala-Leppilampi K, Single E, Robins A. Cannabis law reform in Canada: is the “saga of promise, hesitation and retreat” coming to an end? *Can J Criminol Crim Justice*. 2003;45(3):265–298.
22. Room R, Fischer B, Hall W, Lenton S, Reuter P. *Cannabis Policy: Moving Beyond Stalemate*. New York, NY: Oxford University Press; 2010.
23. Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. *Int J Drug Policy*. 2014;25(4):727–735.
24. Room R. Legalising a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. *Addiction*. 2014;109(3):345–351.
25. Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. *Clin Pharmacol Ther*. 2015;97(6):607–615.
26. Blickman T. *Cannabis Policy Reform in Europe: Bottom Up Rather Than Top Down*. Amsterdam, The Netherlands: Transnational Institute; 2014.
27. Rehm J, Fischer B. Cannabis legalization with strict regulation, the overall superior policy option for public health. *Clin Pharmacol Ther*. 2015;97(6):541–544.
28. Task Force on Cannabis Legalization and Regulation. *A Framework for the Legalization and Regulation of Cannabis in Canada: The Final Report of the Task Force on Cannabis Legalization and Regulation*. Ottawa, ON: Health Canada; 2016.
29. Bondy SJ, Rehm J, Ashley MJ, Walsh G, Single E, Room R. Low-risk drinking guidelines: the scientific evidence. *Can J Public Health*. 1999;90(4):264–270.
30. Rehm J, Patra J. Different guidelines for different countries? On the scientific basis of low-risk drinking guidelines and their implications. *Drug Alcohol Rev*. 2012;31(2):156–161.
31. *Global Recommendations on Physical Activity for Health*. Geneva, Switzerland: World Health Organization; 2010.
32. King JC, Dietary Guidelines Advisory Committee. An evidence-based approach for establishing dietary guidelines. *J Nutr*. 2007;137(2):480–483.
33. Kirby DB. The impact of abstinence and comprehensive sex and STD/HIV education programs on adolescent sexual behavior. *Sex Res Soc Policy*. 2008;5(3):18–27.
34. Hoelscher DM, Evans A, Parcel GS, Kelder SH. Designing effective nutrition interventions for adolescents. *J Am Diet Assoc*. 2002;102(3, suppl):S52–S63.
35. Snyder LB. Health communication campaigns and their impact on behavior. *J Nutr Educ Behav*. 2007;39(2, suppl):S32–S40.
36. Fischer B, Jeffries V, Hall W, Room R, Goldner E, Rehm J. Lower Risk Cannabis Use Guidelines for Canada (LRCUG): a narrative review of evidence and recommendations. *Can J Public Health*. 2011;102(5):324–327.
37. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 2009;6(7):e1000097.
38. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. *BMJ*. 2008;336(7652):1049–1051.
39. From evidence to recommendations: transparent and sensible. GRADE Working Group. 2017. Available at: <http://www.gradeworkinggroup.org>. Accessed December 21, 2016.
40. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Current best practices and standards for development of trustworthy CPGs: Part II, traversing the process. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. *Clinical Practice Guidelines We Can Trust*. Washington, DC: National Academies Press; 2011: 134–169.
41. Eccles M, Clapp Z, Grimshaw J, et al. North of England Evidence Based Guidelines Development Project: methods of guideline development. *BMJ*. 1996;312(7033):760–762.
42. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. *BMJ*. 1999;318(7183):593–596.
43. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. *Curr Pharm Des*. 2014;20(13):2186–2193.
44. Lisdahl KM, Gilbert ER, Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. *Front Psychiatry*. 2013;4:53.
45. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. *JAMA Psychiatry*. 2016;73(3):292–297.
46. James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. *Psychiatry Res Neuroimaging*. 2013;214(3):181–189.
47. Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. *Behav Brain Res*. 2011;220(1):164–172.
48. Jacobus J, Squeglia LM, Sorg SF, Nguyen-Louie TT, Tapert SF. Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence. *J Stud Alcohol Drugs*. 2014;75(5):729–743.
49. Cooley J, Bernier D, Tibbo PG. White matter changes in early phase schizophrenia and cannabis use: an update and systematic review of diffusion tensor imaging studies. *Schizophr Res*. 2014;156(2–3):137–142.
50. Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: a longitudinal study. *Cereb Cortex*. 2017;27(3):1922–1930.
51. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. *Psychopharmacology (Berl)*. 2014;231(8):1455–1465.
52. Schlossarek S, Kempkensteffen J, Reimer J, Verthein U. Psychosocial determinants of cannabis dependence: a systematic review of the literature. *Eur Addict Res*. 2016;22(3):131–144.
53. Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T. Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. *Eur Arch Psychiatry Clin Neurosci*. 2013;263(1):3–13.
54. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. *J Psychopharmacol*. 2005;19(2):187–194.
55. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. *Psychol Addict Behav*. 2012;26(3):496–506.

56. Anthony J. The epidemiology of cannabis dependence. In: Roffman R, Stephens R, eds. *Cannabis Dependence: Its Nature, Consequences and Treatment*. Cambridge, UK: Cambridge University Press; 2006.
57. Fontes MA, Bolla KI, Cunha PJ, et al. Cannabis use before age 15 and subsequent executive functioning. *Br J Psychiatry*. 2011;198(6):442–447.
58. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. *Psychopharmacology (Berl)*. 2011; 216(1):131–144.
59. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey MT. Mental health of teenagers who use cannabis: results of an Australian survey. *Br J Psychiatry*. 2002;180:216–221.
60. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. *Addiction*. 2005;100(3):354–366.
61. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene $\times$ environment interaction. *Biol Psychiatry*. 2005;57(10):1117–1127.
62. McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. *Int J Drug Policy*. 2010;21(1):10–19.
63. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012; 109(40):E2657–E2664.
64. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. *Arch Gen Psychiatry*. 2010;67(5):440–447.
65. Le Strat Y, Dubertret C, Le Foll B. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. *Acad Anal Prev*. 2015;76:1–5.
66. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. *JAMA*. 2003;289(4):427–433.
67. Grant JD, Lynskey MT, Scherrer JF, Agrawal A, Heath AC, Bucholz KK. A cotwin-control analysis of drug use and abuse/dependence risk associated with early-onset cannabis use. *Addict Behav*. 2010;35(1):35–41.
68. Horwood LJ, Fergusson DM, Hayatbakhsh MR, et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. *Drug Alcohol Depend*. 2010;110(3):247–253.
69. Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. *Addiction*. 2003; 98(5):685–692.
70. Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev*. 2012;5(1):32–40.
71. Stogner JM, Miller BL. Assessing the dangers of “dabbing”: mere marijuana or harmful new trend? *Pediatrics*. 2015;136(1):1–3.
72. Pijlman FT, Rigter SM, Hoek J, Goldschmidt HM, Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. *Addict Biol*. 2005;10(2):171–180.
73. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. *PLoS One*. 2013;8(7): e70052.
74. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of delta-9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci*. 2010;55(5):1209–1217.
75. Hall W, Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. *BMJ*. 2015;350:h1205.
76. Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. *Psychol Med*. 2015;45(15): 3181–3189.
77. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry*. 2015;2(3):233–238.
78. Pierre JM, Gandal M, Son M. Cannabis-induced psychosis associated with high potency “wax dabs.” *Schizophr Res*. 2016;172(1-3):211–212.
79. Hunault CC, Mensinga TT, Bocker KB, et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). *Psychopharmacology (Berl)*. 2009;204(1):85–94.
80. van der Pol P, Liebrechts N, Brunt T, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. *Addiction*. 2014;109(7):1101–1109.
81. Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say “know”: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? *Addiction*. 2014;109(10):1686–1694.
82. Batalla A, Crippa JA, Busatto GF, et al. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. *Curr Pharm Des*. 2014; 20(13):2168–2185.
83. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology*. 2010;35(3):764–774.
84. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of D9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. *Curr Pharm Des*. 2012;18(32):4966–4979.
85. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. *Chem Biodivers*. 2007;4(8):1678–1692.
86. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses*. 2006;66(2): 234–246.
87. Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. *Schizophr Res*. 2015;162(1-3):153–161.
88. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. *J Psychopharmacol*. 2013;27(1):19–27.
89. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. *Br J Psychiatry*. 2008;192(4):306–307.
90. Schubart CD, Sommer IE, van Gastel WA, Goetgebuuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. *Schizophr Res*. 2011;130(1-3):216–221.
91. Zornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. *Pharmaceuticals (Basel)*. 2012; 5(5):529–552.
92. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. *J Emerg Med*. 2013; 44(2):360–366.
93. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;39(2):234–243.
94. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. *J Psychopharmacol*. 2015;29(3):254–263.
95. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. *Clin Toxicol (Phila)*. 2016;54(1):1–13.
96. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. *Drug Alcohol Depend*. 2014;144:12–41.
97. Gunderson EW, Haughey HM, AitDaoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. *Am J Addict*. 2012;21(4):320–326.
98. Bush DM, Woodwell DA. Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ Report. Rockville, MD; Substance Abuse and Mental Health Services Administration; 2013.
99. Law R, Schier J, Martin C, Chang A, Wolkin A, Centers for Disease Control and Prevention. Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use—United States, January–May 2015. *MMWR Morb Mortal Wkly Rep*. 2015;64(22): 618–619.
100. Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. *Hum Psychopharmacol*. 2013;28(4):390–393.
101. Murphy F, Sales P, Murphy S, Averill S, Lau N, Sato S. Baby boomers and cannabis delivery systems. *J Drug Issues*. 2015;45(3):293–313.
102. Ialomiteanu AR, Hamilton H, Adlaf E, Mann RE. CAMH Monitor eReport 2015: Substance use, mental health and well-being among Ontario adults. Toronto, ON: Centre for Addiction and Mental Health; 2016.
103. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. *Addiction*. 2012;107(7):1221–1233.
104. Tashkin DP. Increasing cannabis use: what we still need to know about its effects on the lung. *Respirology*. 2014;19(5):619–620.
105. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. *Respirology*. 2014;19(5):655–662.
106. Lee MH, Hancox RJ. Effects of smoking cannabis on lung function. *Expert Rev Respir Med*. 2011;5(4):537–546.

107. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. *JAMA*. 2012;307(2):173–181.
108. Martinasek MP, McGrogan JB, Maysonet A. A systematic review of the respiratory effects of inhalational marijuana. *Respir Care*. 2016;61(11):1543–1551.
109. Tashkin DP, Simmons MS, Tseng CH. Impact of changes in regular use of marijuana and/or tobacco on chronic bronchitis. *COPD*. 2012;9(4):367–374.
110. Hancox RJ, Shin HH, Gray AR, Poulton R, Sears MR. Effects of quitting cannabis on respiratory symptoms. *Eur Respir J*. 2015;46(1):80–87.
111. Fiorelli A, Accardo M, Vicidomini G, Messina G, Laperuta P, Santini M. Does cannabis smoking predispose to lung bulla formation? *Asian Cardiovasc Thorac Ann*. 2014;22(1):65–71.
112. Bouti K, Borki R, Fenane H, Harrak L. Cannabis smoking and risk of lung cancer: a systematic review and meta-analysis. *Int J Med Surg*. 2014;1(2):3–9.
113. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk: a systematic review. *Alcohol*. 2005;35(3):265–275.
114. Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. *Int J Cancer*. 2015;136(4):894–903.
115. Grotenhermen F. Harm reduction associated with inhalation and oral administration of cannabis and THC. *J Cannabis Therapeutics*. 2001;1(3):133–152.
116. Lutchmansingh D, Pawar L, Savici D. Legalizing cannabis: a physician's primer on the pulmonary effects of marijuana. *Curr Respir Care Rep*. 2014;3(4):200–205.
117. Swift W, Copeland J, Lenton S. Cannabis and harm reduction. *Drug Alcohol Rev*. 2000;19:101–112.
118. Tashkin DP. Effects of cannabis on the respiratory system. In: Kalant H, Corrigall W, Hall W, Smart R, eds. *The Health Effects of Cannabis*. Toronto, ON: Addiction Research Foundation; 1999.
119. Thu K, Hayes M, Miles S, Tierney L, Foy A. Marijuana “bong” smoking and tuberculosis. *Intern Med J*. 2013;43(4):456–458.
120. Cozzi NV. Effects of water filtration on marijuana smoke: a literature review. *MAPS Bull*. 1993;4(2):4–6.
121. Gieringer DH. Cannabis vaporization: a promising strategy for smoke harm reduction. *J Cannabis Ther*. 2001;1(3-4):153–170.
122. Gieringer D, St. Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. *J Cannabis Ther*. 2004;4(1):7–27.
123. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (volcano) for the pulmonary administration of tetrahydrocannabinol. *J Pharm Sci*. 2006;95(6):1308–1317.
124. Earleywine M, Van Dam NT. Case studies in cannabis vaporization. *Addict Res Theory*. 2010;18(3):243–249.
125. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. *Int J Drug Policy*. 2010;21(6):511–513.
126. Loflin M, Earleywine M. No smoke, no fire: what the initial literature suggests regarding vaporized cannabis and respiratory risk. *Can J Respir Ther*. 2015;51(1):7–9.
127. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. *N Engl J Med*. 2015;372(4):392–394.
128. Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. *JAMA*. 2015;313(3):241–242.
129. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? *Addict Behav*. 2014;39(10):1430–1433.
130. Wang GS, Roosevelt G, Le Lait MC, et al. Association of unintentional pediatric exposures with decriminalization of marijuana in the United States. *Ann Emerg Med*. 2014;63(6):684–689.
131. Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. *JAMA Pediatr*. 2013;167(7):630–633.
132. Wang GS, Le Lait MC, Deakyn SJ, Bronstein AC, Bajaj L, Roosevelt G. Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. *JAMA Pediatr*. 2016;170(9):e160971.
133. Solowij N, Lorenzetti V, Yucel M. Effects of cannabis use on human behavior: a call for standardization of cannabis use metrics. *JAMA Psychiatry*. 2016;73(9):995–996.
134. *Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings*. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
135. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. *J Affect Disord*. 2015;171:39–47.
136. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007;370(9584):319–328.
137. Reece AS. Chronic toxicology of cannabis. *Clin Toxicol (Phila)*. 2009;47(6):517–524.
138. Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. *Accid Anal Prev*. 2013;60:254–267.
139. Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. *J Affect Disord*. 2016;195:63–74.
140. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M. Structural MRI findings in long-term cannabis users: what do we know? *Subst Use Misuse*. 2010;45(11):1787–1808.
141. Ganzer F, Broning S, Kraft S, Sack P, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of cannabis use in abstinent adolescents and adults. *Neuropsychol Rev*. 2016;26(2):186–222.
142. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. *PLoS One*. 2013;8(2):e55821.
143. Battistella G, Fomari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. *Neuropsychopharmacology*. 2014;39(9):2041–2048.
144. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. *Neuroimage*. 2012;59(4):3845–3851.
145. Lorenzetti V, Solowij N, Whittle S, et al. Gross morphological brain changes with chronic, heavy cannabis use. *Br J Psychiatry*. 2015;206(1):77–78.
146. Yücel M, Lorenzetti V, Suo C, et al. Hippocampal harms, protection and recovery following regular cannabis use. *Transl Psychiatry*. 2016;6:e710.
147. Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. *J Addict Med*. 2011;5(1):1–8.
148. Ramaekers JG, van Wel JH, Spronk DB, et al. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. *Sci Rep*. 2016;6:26843.
149. Schwabe DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood delta (9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. *J Anal Toxicol*. 2012;36(6):405–412.
150. Andréasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. *Acta Psychiatr Scand*. 1989;79(5):505–510.
151. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. *Addiction*. 2004;99(10):1333–1341.
152. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. *Psychol Med*. 2003;33(1):15–21.
153. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. *J Affect Disord*. 2006;95(1-3):103–110.
154. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. *Psychol Med*. 2014;44(4):797–810.
155. van Ours JC, Williams J, Fergusson D, Horwood LJ. Cannabis use and suicidal ideation. *J Health Econ*. 2013;32(3):524–537.
156. Degenhardt L, Coffey C, Romaniuk H, et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. *Addiction*. 2013;108(1):124–133.
157. Coffey C, Carlin JB, Degenhardt L, Lynskey M, Sanci L, Patton GC. Cannabis dependence in young adults: an Australian population study. *Addiction*. 2002;97(2):187–194.
158. van der Pol P, Liebrechts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. *Drug Alcohol Depend*. 2013;133(2):352–359.
159. Silins E, Horwood LJ, Patton GC, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. *Lancet Psychiatry*. 2014;1(4):286–293.
160. Swift W, Coffey C, Degenhardt L, Carlin JB, Romaniuk H, Patton GC. Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. *J Epidemiol Community Health*. 2012;66(7):e26.

161. Patton GC, Coffey C, Lynskey MT, et al. Trajectories of adolescent alcohol and cannabis use into young adulthood. *Addiction*. 2007;102(4):607–615.
162. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. *Drug Alcohol Rev*. 2005;24(1):39–48.
163. Li MC, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle crashes. *Epidemiol Rev*. 2012;34(1):65–72.
164. Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clin Chem*. 2013;59(3):478–492.
165. Zeisser C, Thompson K, Stockwell T, et al. A “standard joint”? The role of quantity in predicting cannabis-related problems. *Addict Res Theory*. 2012;20(1):82–92.
166. Armentano P. Cannabis and psychomotor performance: a rational review of the evidence and implications for public policy. *Drug Test Anal*. 2013;5(1):52–56.
167. Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology (Berl)*. 2006;188(4):425–444.
168. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. *Iran J Psychiatry*. 2012;7(4):149–156.
169. Lee D, Bergamaschi MM, Milman G, et al. Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users. *J Anal Toxicol*. 2015;39(8):580–587.
170. Battistella G, Fornari E, Thomas A, et al. Weed or wheel? fMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. *PLoS One*. 2013;8(1):e52545.
171. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. *Neuropsychopharmacology*. 2006;31(10):2296–2303.
172. Hartman RL, Brown TL, Milavetz G, et al. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. *Drug Test Anal*. 2016;8(7):690–701.
173. Hartman RL, Brown TL, Milavetz G, et al. Effect of blood collection time on measured delta9-tetrahydrocannabinol concentrations: implications for driving interpretation and drug policy. *Clin Chem*. 2016;62(2):367–377.
174. Hunault CC, Bocker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J. Acute subjective effects after smoking joints containing up to 69 mg delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. *Psychopharmacology (Berl)*. 2014;231(24):4723–4733.
175. NHTSA releases two new studies on impaired driving on US roads: drunk driving declines while drug use behind the wheel rises. Washington, DC: National Highway Traffic Safety Administration; 2015.
176. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. *BMJ*. 2012;344:e536.
177. Asbridge M, Mann R, Cusimano MD, et al. Cannabis and traffic collision risk: findings from a case–crossover study of injured drivers presenting to emergency departments. *Int J Public Health*. 2014;59(2):395–404.
178. Ronen A, Chasidim HS, Gershon P, et al. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. *Acid Anal Prev*. 2010;42(6):1855–1865.
179. Hartman RL, Brown TL, Milavetz G, et al. Cannabis effects on driving lateral control with and without alcohol. *Drug Alcohol Depend*. 2015;154:25–37.
180. Downey LA, King R, Papafiotou K, et al. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. *Acid Anal Prev*. 2013;50:879–886.
181. Dubois S, Mullen N, Weaver B, Bedard M. The combined effects of alcohol and cannabis on driving: impact on crash risk. *Forensic Sci Int*. 2015;248:94–100.
182. Sayer G, Ialomiteanu A, Stoduto G, et al. Increased collision risk among drivers who report driving after using alcohol and after using cannabis. *Can J Public Health*. 2014;105(1):e92–e93.
183. Beirness DJ, Porath-Waller AJ. Clearing the smoke on cannabis: cannabis use and driving—an update. Ottawa, ON: Canadian Centre on Substance Abuse; 2015.
184. Cannabis, driving and implications for youth. Ottawa, ON: Canadian Centre on Substance Abuse; 2015.
185. Brady JE, Li G. Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999–2010. *Am J Epidemiol*. 2014;179(6):692–699.
186. Berning A, Compton R, Wochinger K. Results of the 2013–2014 National Roadside Survey of Alcohol and Drug Use by Drivers (traffic safety facts research note). Washington, DC: National Highway Traffic Safety Administration; 2015.
187. Couper FJ, Peterson BL. The prevalence of marijuana in suspected impaired driving cases in Washington State. *J Anal Toxicol*. 2014;38(8):569–574.
188. Berghaus G, Sticht G, Grellner W, Lenz D, Naumann T, Wiesenmüller S. Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. In: *Driving Under the Influence of Drugs, Alcohol, and Medicines (DRUID) 6th Framework Programme*. Brussels, Belgium: European Commission; 2011:168–176.
189. Verstraete A, Knoche A, Jantos R, et al. Per se limits: methods of defining cut-off values for zero tolerance. In: *Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) 6th Framework Programme*. Brussels, Belgium: European Commission; 2011.
190. Vindenes V, Jordbru D, Knapskog AB, et al. Impairment based legislative limits for driving under the influence of non-alcohol drugs in Norway. *Forensic Sci Int*. 2012;219(1–3):1–11.
191. Wong K, Brady JE, Li G. Establishing legal limits for driving under the influence of marijuana. *Inj Epidemiol*. 2014;1(1):26.
192. Hall W, Homel R. Reducing cannabis-impaired driving: is there sufficient evidence for drug testing of drivers? *Addiction*. 2007;102(12):1918–1919.
193. Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. *Psychol Med*. 2016;46(4):673–681.
194. Di Forti M, Iyegbe C, Falcone A, Powell J, Murray R. Vulnerability to cannabis-related psychosis: association with frequency and potency of cannabis use, and interaction with genes regulating dopamine signalling. *Lancet*. 2014;383(suppl 1):S41.
195. Giordano GN, Ohlsson H, Sundquist K, Sundquist J, Kendler KS. The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. *Psychol Med*. 2015;45(2):407–414.
196. Power RA, Verweij KJ, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. *Mol Psychiatry*. 2014;19(11):1201–1204.
197. Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot—a review of the association between cannabis and psychosis. *Front Psychiatry*. 2014;5:54.
198. Degenhardt L, Hall W, Lynskey M, et al. Should burden of disease estimates include cannabis use as a risk factor for psychosis? *PLoS Med*. 2009;6(9):e1000133.
199. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies. *BMC Psychiatry*. 2014;14(136):1–22.
200. Lai HM, Sitharthan T. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. *Am J Drug Alcohol Abuse*. 2012;38(6):567–574.
201. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P. Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts. *BMC Psychiatry*. 2012;12(112):1–7.
202. Shalit N, Shoval G, Shlosberg D, Feingold D, Lev-Ran S. The association between cannabis use and suicidality among men and women: a population-based longitudinal study. *J Affect Disord*. 2016;205:216–224.
203. Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. *Clin Chem*. 2010;56(9):1442–1450.
204. Day NL, Leech SL, Goldschmidt L. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. *Neurotoxicol Teratol*. 2011;33(1):129–136.
205. Sonon KE, Richardson GA, Cornelius JR, Kim KH, Day NL. Prenatal marijuana exposure predicts marijuana use in young adulthood. *Neurotoxicol Teratol*. 2015;47:10–15.
206. Willford JA, Chandler LS, Goldschmidt L, Day NL. Effects of prenatal tobacco, alcohol and marijuana exposure on processing speed, visual-motor coordination, and interhemispheric transfer. *Neurotoxicol Teratol*. 2010;32(6):580–588.
207. Goldschmidt L, Richardson GA, Larkby C, Day NL. Early marijuana initiation: the link between prenatal marijuana exposure, early childhood behavior, and negative adult roles. *Neurotoxicol Teratol*. 2016;58:40–45.
208. Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). *Cancer*. 1989;63(10):1904–1911.
209. Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. *Cancer Causes Control*. 1993;4(3):217–224.
210. Kuijten RR, Bunin GR, Nass CC, Meadows AT. Parental occupation and childhood astrocytoma: results of a case–control study. *Cancer Res*. 1992;52(4):782–786.

211. Ramsey G. Getting regulation right: assessing Uruguay's historic cannabis initiative. Washington, DC: Washington Office on Latin America; 2016.
212. Hall W, Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. *Addiction*. 2016;111(10):1764–1773.
213. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP. Developing public health regulations for marijuana: lessons from alcohol and tobacco. *Am J Public Health*. 2014;104(6):1021–1028.
214. Haden M, Emerson B. A vision for cannabis regulation: a public health approach based on lessons learned from the regulation of alcohol and tobacco. *Open Med*. 2014;8(2):e73–e80.
215. Patton GC, Coffey C, Carlin J, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. *BMJ*. 2002;325(7374):1195–1198.
216. Hanson MD, Chen E. Socioeconomic status and health behaviors in adolescence: a review of the literature. *J Behav Med*. 2007;30(3):263–285.
217. McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. *Addiction*. 2000;95(4):491–503.
218. Lemstra M, Bennett NR, Neudorf C, et al. A meta-analysis of marijuana and alcohol use by socioeconomic status in adolescents aged 10–15 years. *Can J Public Health*. 2008;99(3):172–177.
219. Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. *Arch Gen Psychiatry*. 2008;65(6):674–682.
220. Lynskey MT, Heath AC, Nelson EC, et al. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. *Psychol Med*. 2002;32(2):195–207.
221. LaRocca R, Yost J, Dobbins M, Ciliska D, Butt M. The effectiveness of knowledge translation strategies used in public health: a systematic review. *BMC Public Health*. 2012;12:751.
222. Mitton C, Adair CE, McKenzie E, Patten SB, Wayne Perry B. Knowledge transfer and exchange: review and synthesis of the literature. *Milbank Q*. 2007;85(4):729–768.
223. Lovatt M, Eadie D, Meier PS, et al. Lay epidemiology and the interpretation of low-risk drinking guidelines by adults in the United Kingdom. *Addiction*. 2015;110(12):1912–1919.
224. Moss AC, Dyer KR, Albery IP. Knowledge of drinking guidelines does not equal sensible drinking. *Lancet*. 2009;374(9697):1242.